BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: Impact on diagnosis and prognosis

Acta Cytologica

Volumn 55, Issue 6, 2011, Pages 563-569

  Colanta, Agnes ^a   Lin, Oscar ^a   Tafe, Laura ^a   Ghossein, Ronald ^a   Nafa, Khedoudja ^a   Mitchell, Talia ^a   Ladanyi, Marc ^a   Arcila, Maria ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRAF; Papillary carcinoma; Prognosis; Thyroid

Indexed keywords

B RAF KINASE; DNA;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER RECURRENCE; CYTOLOGY; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PAPILLARY THYROID CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; THYROID CARCINOMA;

EID: 83455181376     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000333272     Document Type: Article

References (29)

1. Nikiforova MN, Nikiforov YE: Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009; 19: 1351-1361.
2. Xing M: Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010; 321: 86-93.
3. Nucera C, Lawler J, Hodin R, Parangi S: The BRAF V600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget 2010; 1: 751-756.
4. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470, discussion 470-461. (Pubitemid 47312140)
5. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE: Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009; 146: 1215-1223.
6. Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, Pinchera A, Bevilacqua G: A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 2009; 19: 837-842.
7. Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC: Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid 2011; 21: 717-723.
8. Arcila M, Lau C, Nafa K, Ladanyi M: Detection of KRAS and BRAS mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011; 13: 64-73.
9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mc-Iver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
10. Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: a study of 4,703 patients with histologic and clinical correlations. Cancer 2007; 111: 306-315.
11. Cibas ES, Ali SZ: The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009; 132: 658-665.
12. Kesmodel SB, Terhune KP, Canter RJ, Mandel SJ, LiVolsi VA, Baloch ZW, Fraker DL: The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. Surgery 2003; 134: 1005-1012, discussion 1012. (Pubitemid 38010747)
13. Brzezianska E, Pastuszak-Lewandoska D: A minireview: the role of MARK/ERK and PI3K/Akt pathways in thyroid follicular cellderived neoplasm. Front Biosci 2011; 16: 422-439.
14. Vriens MR, Schreinemakers JM, Suh I, Guerrero MA, Clark OH: Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol 2009; 5: 1283-1293.
15. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005; 446: 589-595. (Pubitemid 40922263)
16. Shibru D, Chung KW, Kebebew E: Recent developments in the clinical application of thyroid cancer biomarkers. Curr Opin Oncol 2008; 20: 13-18. (Pubitemid 350190976)
17. Melck AL, Yip L, Carty SE: The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist 2010; 15: 1285-1293.
18. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN: Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-2098.
19. Ohori NP, Nikiforova MN, Schoedel KE, Le-Beau SO, Hodak SP, Seethala RR, Carty SE, Ogilvie JB, Yip L, Nikiforov YE: Contribution of molecular testing to thyroid fine-needle aspiration cytology of 'follicular lesion of undetermined significance/atypia of undetermined significance'. Cancer Cytopathol 2010; 118: 17-23.
20. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA: Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs. infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010; 23: 1191-1200.
21. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Natargeting to the membrane. Endocr Relat Cancer 2006; 13: 257-269.
22. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM: The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 2010; 17: 3294-3300.
23. Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK: Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 2011; 42: 500-506.
24. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC: BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009; 161: 467-473.
25. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M: Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004; 89: 5175-5180. (Pubitemid 39391466)
26. Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, Moon WJ, Oh SY, Hwang TS: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008; 17: 118-125.
27. Kwak JY, Kim EK, Kim JK, Han JH, Hong SW, Park TS, Choi JR: Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. Head Neck 2010; 32: 490-498.
28. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS: Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011; 96: 658-664.
29. Bentz BG, Miller BT, Holden JA, Rowe LR, Bentz JS: B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules. Otolaryngol Head Neck Surg 2009; 140: 709-714.